Role of MRI at 1- and 3-Month Follow-up in Predicting the Likelihood of Tumor Recurrence Following Percutaneous Cryoablation of Renal Tumors.
Cryosurgery
Imaging
Kidney neoplasm
Magnetic resonance
Journal
Cardiovascular and interventional radiology
ISSN: 1432-086X
Titre abrégé: Cardiovasc Intervent Radiol
Pays: United States
ID NLM: 8003538
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
08
01
2023
accepted:
22
04
2023
medline:
5
6
2023
pubmed:
16
5
2023
entrez:
16
5
2023
Statut:
ppublish
Résumé
To evaluate whether ablation volume difference relatively to tumoral volume, minimal distance between ablation area and necrotic tumor, or apparent diffusion coefficient (ADC) within the ablation area, measured on 1- and 3-month follow-up MRI following cryoablation of renal tumors, are associated with tumor recurrence. 136 renal tumors were retrospectively identified. Patients, tumor characteristics and follow-up MRI (1-, 3-, 6-month, and thereafter annually) were collected. Uni- and multivariate analyses were performed to assess the association between the investigated parameters and tumor recurrence. Over the follow-up period (27.7 ± 21.9 months), 13 recurrences were identified at 20.5 ± 19.4 months. At 1- and 3-month, the mean volume difference between the ablation zone and the tumor volume were + 577.5 ± 511.3% vs + 251.4 ± 209.8% (p = 0.003), and + 268.8 ± 291.1% vs + 103.8 ± 94.6% (p = 0.023) in patients without and with tumor recurrence, respectively. At 1- and 3-month, the minimum distance between the necrotic tumor and the edge of the ablation area was 3.4 ± 2.5 vs 1.8 ± 1.9 mm (p = 0.019), and 2.4 ± 2.3 vs 1.4 ± 1.8 mm (p = 0.13) in patients without and with tumor recurrence, respectively. Analysis of ADC values was not associated with tumor recurrence. After performing the multivariate analysis, only volume difference of the ablation area compared to tumor volume was associated with absence of tumor recurrence at 1- (OR = 14.1; p = 0.001) and 3-month (OR = 8.2; p = 0.01). Evaluation of volume difference between the ablation area and tumor volume on early (≤ 3 months) MRI follow-up identifies patients at risk of tumor recurrence.
Identifiants
pubmed: 37191935
doi: 10.1007/s00270-023-03452-8
pii: 10.1007/s00270-023-03452-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
777-785Informations de copyright
© 2023. Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
doi: 10.3322/caac.21660
pubmed: 33538338
Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernández-Pello S, et al. European association of urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol. 2019;75:799–810.
doi: 10.1016/j.eururo.2019.02.011
pubmed: 30803729
Psutka SP, Feldman AS, McDougal WS, McGovern FJ, Mueller P, Gervais DA. Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma. Eur Urol. 2013;63:486–92.
doi: 10.1016/j.eururo.2012.08.062
pubmed: 22959191
Lim E, Kumar S, Seager M, Modi S, Mandal I, Neves JB, et al. Outcomes of renal tumors treated by image-guided percutaneous cryoablation: immediate and 3- and 5-year outcomes at a regional center. AJR Am J Roentgenol. 2020;215:242–7.
doi: 10.2214/AJR.19.22213
pubmed: 32286877
Krokidis ME, Orsi F, Katsanos K, Helmberger T, Adam A. CIRSE guidelines on percutaneous ablation of small renal cell carcinoma. Cardiovasc Intervent Radiol. 2017;40:177–91.
doi: 10.1007/s00270-016-1531-y
pubmed: 27987000
Correas J-M, Delavaud C, Gregory J, Le Guilchet T, Lamhaut L, Timsit M-O, et al. Ablative therapies for renal tumors: patient selection, treatment planning, and follow-up. Semin Ultrasound CT MR. 2017;38:78–95.
doi: 10.1053/j.sult.2016.11.009
pubmed: 28237283
Garnon J. The money time for decision-making. Cardiovasc Intervent Radiol. 2021;44:901–2.
doi: 10.1007/s00270-021-02813-5
pubmed: 33754177
Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S, et al. European association of urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol [Internet]. 2022 [cited 2022 Aug 25]; https://www.sciencedirect.com/science/article/pii/S0302283822016761
Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol Elsevier. 2019;30:706–20.
doi: 10.1093/annonc/mdz056
Krokidis ME, Orsi F, Katsanos K, Helmberger T, Adam A. CIRSE guidelines on percutaneous ablation of small renal cell carcinoma. Cardiovasc Interv Radiol. 2017;40:177–91.
doi: 10.1007/s00270-016-1531-y
Allen BC, Remer EM. Percutaneous cryoablation of renal tumors: patient selection, technique, and postprocedural imaging <sup/>. Radiographics. 2010;30:887–900.
doi: 10.1148/rg.304095134
pubmed: 20631358
De Marini P, Cazzato RL, Garnon J, Dalili D, Leonard-Lorant I, Leclerc L, et al. Safety and oncologic efficacy of percutaneous MRI-guided cryoablation of intraparenchymal renal cancers. Diagn Interv Imaging. 2021;102:531–8.
doi: 10.1016/j.diii.2021.04.002
pubmed: 33931365
Koch G, Cazzato RL, Caudrelier J, Cathelineau X, Lang H, Gangi A. Techniques d’ablation tumorale. Prog En Urol. 2017;27:853–64.
doi: 10.1016/j.purol.2017.07.244
Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria—A 10-year update. Radiology. 2014;273:241–60.
doi: 10.1148/radiol.14132958
pubmed: 24927329
Lee H-J, Chung H-J, Wang H-K, Shen S-H, Chang Y-H, Chen C-K, et al. Evolutionary magnetic resonance appearance of renal cell carcinoma after percutaneous cryoablation. Br J Radiol. 2016;89:20160151.
doi: 10.1259/bjr.20160151
pubmed: 27401340
pmcid: 5124922
Kawamoto S, Solomon SB, Bluemke DA, Fishman EK. Computed tomography and magnetic resonance imaging appearance of renal neoplasms after radiofrequency ablation and cryoablation. Semin Ultrasound CT MRI. 2009;30:67–77.
doi: 10.1053/j.sult.2008.12.005
Durack JC, Richioud B, Lyon J, Solomon SB. Late emergence of contrast-enhancing fat necrosis mimicking tumor seeding after renal cryoablation. J Vasc Interv Radiol JVIR. 2014;25:133–7.
doi: 10.1016/j.jvir.2013.07.006
pubmed: 24365507
Wile GE, Leyendecker JR, Krehbiel KA, Dyer RB, Zagoria RJ. CT and MR imaging after imaging-guided thermal ablation of renal neoplasms. Radiographics. 2007;27:325–39.
doi: 10.1148/rg.272065083
pubmed: 17374856
Garnon J, Tricard T, Cazzato RL, Cathelineau X, Gangi A, Lang H. Traitement ablatif pour cancer du rein: modalités d’évaluation pré-, per-, post-intervention et prise en charge adaptée. Prog En Urol. 2017;27:971–93.
doi: 10.1016/j.purol.2017.08.007
Davenport MS, Perazella MA, Yee J, Dillman JR, Fine D, McDonald RJ, et al. Use of intravenous iodinated contrast media in patients with kidney disease: consensus statements from the american college of radiology and the national kidney foundation. Radiology. 2020;294:660–8.
doi: 10.1148/radiol.2019192094
pubmed: 31961246
Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:706–20.
doi: 10.1093/annonc/mdz056
pubmed: 30788497
Laimer G, Jaschke N, Schullian P, Putzer D, Eberle G, Solbiati M, et al. Volumetric assessment of the periablational safety margin after thermal ablation of colorectal liver metastases. Eur Radiol. 2021;31:6489–99.
doi: 10.1007/s00330-020-07579-x
pubmed: 33447860
pmcid: 8379110
Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures. They Are Data Radiology. 2016;278:563–77.
pubmed: 26579733
Tsili AC, Andriotis E, Gkeli MG, Krokidis M, Stasinopoulou M, Varkarakis IM, et al. The role of imaging in the management of renal masses. Eur J Radiol. 2021;141: 109777.
doi: 10.1016/j.ejrad.2021.109777
pubmed: 34020173
Li A, Xing W, Li H, Hu Y, Hu D, Li Z, et al. Subtype Differentiation of small (≤ 4 cm) solid renal mass using volumetric histogram analysis of DWI at 3-T MRI. AJR Am J Roentgenol. 2018;211:614–23.
doi: 10.2214/AJR.17.19278
pubmed: 29812980